<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35563042</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1422-0067</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>22</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of molecular sciences</Title>
          <ISOAbbreviation>Int J Mol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Identification of Potential Muscle Biomarkers in McArdle Disease: Insights from Muscle Proteome Analysis.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">4650</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms23094650</ELocationID>
        <Abstract>
          <AbstractText>Glycogen storage disease type V (GSDV, McArdle disease) is a rare genetic myopathy caused by deficiency of the muscle isoform of glycogen phosphorylase (PYGM). This results in a block in the use of muscle glycogen as an energetic substrate, with subsequent exercise intolerance. The pathobiology of GSDV is still not fully understood, especially with regard to some features such as persistent muscle damage (i.e., even without prior exercise). We aimed at identifying potential muscle protein biomarkers of GSDV by analyzing the muscle proteome and the molecular networks associated with muscle dysfunction in these patients. Muscle biopsies from eight patients and eight healthy controls showing none of the features of McArdle disease, such as frequent contractures and persistent muscle damage, were studied by quantitative protein expression using isobaric tags for relative and absolute quantitation (iTRAQ) followed by artificial neuronal networks (ANNs) and topology analysis. Protein candidate validation was performed by Western blot. Several proteins predominantly involved in the process of muscle contraction and/or calcium homeostasis, such as myosin, sarcoplasmic/endoplasmic reticulum calcium ATPase 1, tropomyosin alpha-1 chain, troponin isoforms, and alpha-actinin-3, showed significantly lower expression levels in the muscle of GSDV patients. These proteins could be potential biomarkers of the persistent muscle damage in the absence of prior exertion reported in GSDV patients. Further studies are needed to elucidate the molecular mechanisms by which PYGM controls the expression of these proteins.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>García-Consuegra</LastName>
            <ForeName>Inés</ForeName>
            <Initials>I</Initials>
            <Identifier Source="ORCID">0000-0003-1717-7446</Identifier>
            <AffiliationInfo>
              <Affiliation>Mitochondrial and Neuromuscular Disorders Group, Hospital 12 de Octubre Health Research Institute (imas12), 28041 Madrid, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Asensio-Peña</LastName>
            <ForeName>Sara</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-2048-5899</Identifier>
            <AffiliationInfo>
              <Affiliation>Mitochondrial and Neuromuscular Disorders Group, Hospital 12 de Octubre Health Research Institute (imas12), 28041 Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Garrido-Moraga</LastName>
            <ForeName>Rocío</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0002-2856-4399</Identifier>
            <AffiliationInfo>
              <Affiliation>Mitochondrial and Neuromuscular Disorders Group, Hospital 12 de Octubre Health Research Institute (imas12), 28041 Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pinós</LastName>
            <ForeName>Tomàs</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Mitochondrial and Neuromuscular Disorders Unit, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Domínguez-González</LastName>
            <ForeName>Cristina</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0001-5151-988X</Identifier>
            <AffiliationInfo>
              <Affiliation>Mitochondrial and Neuromuscular Disorders Group, Hospital 12 de Octubre Health Research Institute (imas12), 28041 Madrid, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Santalla</LastName>
            <ForeName>Alfredo</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0001-9418-0564</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Computer and Sport Sciences, Universidad Pablo de Olavide, 41013 Sevilla, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nogales-Gadea</LastName>
            <ForeName>Gisela</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Grup de Recerca en Malalties Neuromusculars i Neuropediàtriques, Department of Neurosciences, Institut d'Investigacio en Ciencies de la Salut Germans Trias i Pujol i Campus Can Ruti, Universitat Autònoma de Barcelona, 08916 Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Serrano-Lorenzo</LastName>
            <ForeName>Pablo</ForeName>
            <Initials>P</Initials>
            <Identifier Source="ORCID">0000-0002-5661-7574</Identifier>
            <AffiliationInfo>
              <Affiliation>Mitochondrial and Neuromuscular Disorders Group, Hospital 12 de Octubre Health Research Institute (imas12), 28041 Madrid, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Andreu</LastName>
            <ForeName>Antoni L</ForeName>
            <Initials>AL</Initials>
            <AffiliationInfo>
              <Affiliation>EATRIS, European Infrastructure for Translational Medicine, 1019 Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arenas</LastName>
            <ForeName>Joaquín</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Mitochondrial and Neuromuscular Disorders Group, Hospital 12 de Octubre Health Research Institute (imas12), 28041 Madrid, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zugaza</LastName>
            <ForeName>José L</ForeName>
            <Initials>JL</Initials>
            <Identifier Source="ORCID">0000-0002-9000-6398</Identifier>
            <AffiliationInfo>
              <Affiliation>Achucarro Basque Center for Neuroscience, Science Park of the UPV/EHU, and Department of Genetics, Physical Anthropology, and Animal Physiology, Faculty of Science and Technology, UPV/EHU, 48940 Leioa, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>IKERBASQUE, Basque Foundation for Science, Plaza Euskadi 5, 48009 Bilbao, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lucia</LastName>
            <ForeName>Alejandro</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Mitochondrial and Neuromuscular Disorders Group, Hospital 12 de Octubre Health Research Institute (imas12), 28041 Madrid, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Sport Sciences, Universidad Europea de Madrid, 28670 Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Martín</LastName>
            <ForeName>Miguel A</ForeName>
            <Initials>MA</Initials>
            <Identifier Source="ORCID">0000-0003-4741-772X</Identifier>
            <AffiliationInfo>
              <Affiliation>Mitochondrial and Neuromuscular Disorders Group, Hospital 12 de Octubre Health Research Institute (imas12), 28041 Madrid, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int J Mol Sci</MedlineTA>
        <NlmUniqueID>101092791</NlmUniqueID>
        <ISSNLinking>1422-0067</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020543">Proteome</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9005-79-2</RegistryNumber>
          <NameOfSubstance UI="D006003">Glycogen</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006003" MajorTopicYN="N">Glycogen</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006012" MajorTopicYN="Y">Glycogen Storage Disease Type V</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020543" MajorTopicYN="N">Proteome</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">GSDV</Keyword>
        <Keyword MajorTopicYN="N">McArdle disease</Keyword>
        <Keyword MajorTopicYN="N">PYGM</Keyword>
        <Keyword MajorTopicYN="N">iTRAQ</Keyword>
        <Keyword MajorTopicYN="N">metabolic myopathy</Keyword>
        <Keyword MajorTopicYN="N">myophosphorylase</Keyword>
        <Keyword MajorTopicYN="N">protein biomarkers</Keyword>
        <Keyword MajorTopicYN="N">proteomics</Keyword>
        <Keyword MajorTopicYN="N">skeletal muscle</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>1</Hour>
          <Minute>3</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35563042</ArticleId>
        <ArticleId IdType="pmc">PMC9100117</ArticleId>
        <ArticleId IdType="doi">10.3390/ijms23094650</ArticleId>
        <ArticleId IdType="pii">ijms23094650</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Nogales-Gadea G., Brull A., Santalla A., Andreu A.L., Arenas J., Martin M.A., Lucia A., de Luna N., Pinos T. McArdle Disease: Update of Reported Mutations and Polymorphisms in the PYGM Gene. Hum. Mutat. 2015;36:669–678. doi: 10.1002/humu.22806.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/humu.22806</ArticleId>
            <ArticleId IdType="pubmed">25914343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santalla A., Nogales-Gadea G., Encinar A.B., Vieitez I., Gonzalez-Quintana A., Serrano-Lorenzo P., Consuegra I.G., Asensio S., Ballester-Lopez A., Pintos-Morell G., et al.  Genotypic and phenotypic features of all Spanish patients with McArdle disease: A 2016 update. BMC Genom. 2017;18((Suppl. S8)):819. doi: 10.1186/s12864-017-4188-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12864-017-4188-2</ArticleId>
            <ArticleId IdType="pmc">PMC5688471</ArticleId>
            <ArticleId IdType="pubmed">29143597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haller R.G. Treatment of McArdle disease. Arch. Neurol. 2000;57:923–924. doi: 10.1001/archneur.57.7.923.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.57.7.923</ArticleId>
            <ArticleId IdType="pubmed">10891971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lucia A., Ruiz J.R., Santalla A., Nogales-Gadea G., Rubio J.C., Garcia-Consuegra I., Cabello A., Perez M., Teijeira S., Vieitez I., et al.  Genotypic and phenotypic features of McArdle disease: Insights from the Spanish national registry. J. Neurol. Neurosurg. Psychiatry. 2012;83:322–328. doi: 10.1136/jnnp-2011-301593.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2011-301593</ArticleId>
            <ArticleId IdType="pubmed">22250184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Castro M., Johnston J., Biesecker L. Determining the prevalence of McArdle disease from gene frequency by analysis of next-generation sequencing data. Genet. Med. 2015;17:1002–1006. doi: 10.1038/gim.2015.9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/gim.2015.9</ArticleId>
            <ArticleId IdType="pmc">PMC4561039</ArticleId>
            <ArticleId IdType="pubmed">25741863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Llavero F., Arrazola Sastre A., Luque Montoro M., Galvez P., Lacerda H.M., Parada L.A., Zugaza J.L. McArdle Disease: New Insights into Its Underlying Molecular Mechanisms. Int. J. Mol. Sci. 2019;20:5919.  doi: 10.3390/ijms20235919.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms20235919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scalco R.S., Lucia A., Santalla A., Martinuzzi A., Vavla M., Reni G., Toscano A., Musumeci O., Voermans N.C., Kouwenberg C.V., et al.  Data from the European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC) Orphanet J. Rare Dis. 2020;15:330. doi: 10.1186/s13023-020-01562-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13023-020-01562-x</ArticleId>
            <ArticleId IdType="pmc">PMC7687836</ArticleId>
            <ArticleId IdType="pubmed">33234167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santalla A., Nogales-Gadea G., Ortenblad N., Brull A., de Luna N., Pinos T., Lucia A. McArdle disease: A unique study model in sports medicine. Sports Med. 2014;44:1531–1544. doi: 10.1007/s40279-014-0223-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40279-014-0223-5</ArticleId>
            <ArticleId IdType="pubmed">25028051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Consuegra I., Rubio J.C., Nogales-Gadea G., Bautista J., Jimenez S., Cabello A., Lucia A., Andreu A.L., Arenas J., Martin M.A. Novel mutations in patients with McArdle disease by analysis of skeletal muscle mRNA. J. Med. Genet. 2009;46:198–202. doi: 10.1136/jmg.2008.059469.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jmg.2008.059469</ArticleId>
            <ArticleId IdType="pubmed">19251976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Consuegra I., Asensio-Pena S., Ballester-Lopez A., Francisco-Velilla R., Pinos T., Pintos-Morell G., Coll-Canti J., Gonzalez-Quintana A., Andreu A.L., Arenas J., et al.  Missense mutations have unexpected consequences: The McArdle disease paradigm. Hum. Mutat. 2018;39:1338–1343. doi: 10.1002/humu.23591.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/humu.23591</ArticleId>
            <ArticleId IdType="pubmed">30011114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Godfrey R., Quinlivan R. Skeletal muscle disorders of glycogenolysis and glycolysis. Nat. Rev. Neurol. 2016;12:393–402. doi: 10.1038/nrneurol.2016.75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrneurol.2016.75</ArticleId>
            <ArticleId IdType="pubmed">27231184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vissing J., Duno M., Schwartz M., Haller R.G. Splice mutations preserve myophosphorylase activity that ameliorates the phenotype in McArdle disease. Pt 6Brain. 2009;132:1545–1552. doi: 10.1093/brain/awp065.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awp065</ArticleId>
            <ArticleId IdType="pubmed">19433441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lucia A., Nogales-Gadea G., Perez M., Martin M.A., Andreu A.L., Arenas J. McArdle disease: What do neurologists need to know? Nat. Clin. Pract. Neurol. 2008;4:568–577. doi: 10.1038/ncpneuro0913.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncpneuro0913</ArticleId>
            <ArticleId IdType="pubmed">18833216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haller R.G., Clausen T., Vissing J. Reduced levels of skeletal muscle Na+K+ -ATPase in McArdle disease. Neurology. 1998;50:37–40. doi: 10.1212/WNL.50.1.37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.50.1.37</ArticleId>
            <ArticleId IdType="pubmed">9443454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evans C., Noirel J., Ow S.Y., Salim M., Pereira-Medrano A.G., Couto N., Pandhal J., Smith D., Pham T.K., Karunakaran E., et al.  An insight into iTRAQ: Where do we stand now? Anal. Bioanal. Chem. 2012;404:1011–1027. doi: 10.1007/s00216-012-5918-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00216-012-5918-6</ArticleId>
            <ArticleId IdType="pubmed">22451173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Artigas L., Coma M., Matos-Filipe P., Aguirre-Plans J., Farres J., Valls R., Fernandez-Fuentes N., de la Haba-Rodriguez J., Olvera A., Barbera J., et al.  In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm. PLoS ONE. 2020;15:e0240149.  doi: 10.1371/journal.pone.0240149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0240149</ArticleId>
            <ArticleId IdType="pmc">PMC7531795</ArticleId>
            <ArticleId IdType="pubmed">33006999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jorba G., Aguirre-Plans J., Junet V., Segu-Verges C., Ruiz J.L., Pujol A., Fernandez-Fuentes N., Mas J.M., Oliva B. In-silico simulated prototype-patients using TPMS technology to study a potential adverse effect of sacubitril and valsartan. PLoS ONE. 2020;15:e0228926.  doi: 10.1371/journal.pone.0228926.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0228926</ArticleId>
            <ArticleId IdType="pmc">PMC7018085</ArticleId>
            <ArticleId IdType="pubmed">32053711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gimenez N., Tripathi R., Giro A., Rosich L., Lopez-Guerra M., Lopez-Oreja I., Playa-Albinyana H., Arenas F., Mas J.M., Perez-Galan P., et al.  Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia. Sci. Rep. 2020;10:22153. doi: 10.1038/s41598-020-78315-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-020-78315-0</ArticleId>
            <ArticleId IdType="pmc">PMC7746765</ArticleId>
            <ArticleId IdType="pubmed">33335123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herrando-Grabulosa M., Mulet R., Pujol A., Mas J.M., Navarro X., Aloy P., Coma M., Casas C. Novel Neuroprotective Multicomponent Therapy for Amyotrophic Lateral Sclerosis Designed by Networked Systems. PLoS ONE. 2016;11:e0147626.  doi: 10.1371/journal.pone.0147626.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0147626</ArticleId>
            <ArticleId IdType="pmc">PMC4726541</ArticleId>
            <ArticleId IdType="pubmed">26807587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Romeo-Guitart D., Fores J., Herrando-Grabulosa M., Valls R., Leiva-Rodriguez T., Galea E., Gonzalez-Perez F., Navarro X., Petegnief V., Bosch A., et al.  Neuroprotective Drug for Nerve Trauma Revealed Using Artificial Intelligence. Sci. Rep. 2018;8:1879. doi: 10.1038/s41598-018-19767-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-018-19767-3</ArticleId>
            <ArticleId IdType="pmc">PMC5790005</ArticleId>
            <ArticleId IdType="pubmed">29382857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fiuza-Luces C., Santos-Lozano A., Llavero F., Campo R., Nogales-Gadea G., Diez-Bermejo J., Baladron C., Gonzalez-Murillo A., Arenas J., Martin M.A., et al.  Muscle molecular adaptations to endurance exercise training are conditioned by glycogen availability: A proteomics-based analysis in the McArdle mouse model. J. Physiol. 2018;596:1035–1061. doi: 10.1113/JP275292.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1113/JP275292</ArticleId>
            <ArticleId IdType="pmc">PMC5851888</ArticleId>
            <ArticleId IdType="pubmed">29315579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riffo-Campos A.L., Fuentes-Trillo A., Tang W.Y., Soriano Z., De Marco G., Rentero-Garrido P., Adam-Felici V., Lendinez-Tortajada V., Francesconi K., Goessler W., et al.  In silico epigenetics of metal exposure and subclinical atherosclerosis in middle aged men: Pilot results from the Aragon Workers Health Study. Philos. Trans. R Soc. Lond. B Biol. Sci. 2018;373:20170084. doi: 10.1098/rstb.2017.0084.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1098/rstb.2017.0084</ArticleId>
            <ArticleId IdType="pmc">PMC5915723</ArticleId>
            <ArticleId IdType="pubmed">29685964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santos-Lozano A., Fiuza-Luces C., Fernandez-Moreno D., Llavero F., Arenas J., Lopez J.A., Vazquez J., Escribano-Subias P., Zugaza J.L., Lucia A. Exercise Benefits in Pulmonary Hypertension. J. Am. Coll. Cardiol. 2019;73:2906–2907. doi: 10.1016/j.jacc.2019.03.489.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacc.2019.03.489</ArticleId>
            <ArticleId IdType="pubmed">31171100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinuzzi A., Sartori E., Fanin M., Nascimbeni A., Valente L., Angelini C., Siciliano G., Mongini T., Tonin P., Tomelleri G., et al.  Phenotype modulators in myophosphorylase deficiency. Ann. Neurol. 2003;53:497–502. doi: 10.1002/ana.10499.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.10499</ArticleId>
            <ArticleId IdType="pubmed">12666117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nogales-Gadea G., Godfrey R., Santalla A., Coll-Canti J., Pintos-Morell G., Pinos T., Arenas J., Martin M.A., Lucia A. Genes and exercise intolerance: Insights from McArdle disease. Physiol. Genom. 2016;48:93–100. doi: 10.1152/physiolgenomics.00076.2015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/physiolgenomics.00076.2015</ArticleId>
            <ArticleId IdType="pubmed">26465709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shannon P., Markiel A., Ozier O., Baliga N.S., Wang J.T., Ramage D., Amin N., Schwikowski B., Ideker T. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498–2504. doi: 10.1101/gr.1239303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gr.1239303</ArticleId>
            <ArticleId IdType="pmc">PMC403769</ArticleId>
            <ArticleId IdType="pubmed">14597658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quinlan K.G., Seto J.T., Turner N., Vandebrouck A., Floetenmeyer M., Macarthur D.G., Raftery J.M., Lek M., Yang N., Parton R.G., et al.  Alpha-actinin-3 deficiency results in reduced glycogen phosphorylase activity and altered calcium handling in skeletal muscle. Hum. Mol. Genet. 2010;19:1335–1346. doi: 10.1093/hmg/ddq010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddq010</ArticleId>
            <ArticleId IdType="pubmed">20089531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lucia A., Gomez-Gallego F., Santiago C., Perez M., Mate-Munoz J.L., Chamorro-Vina C., Nogales-Gadea G., Foster C., Rubio J.C., Andreu A.L., et al.  The 577X allele of the ACTN3 gene is associated with improved exercise capacity in women with McArdle’s disease. Neuromuscul. Disord. 2007;17:603–610. doi: 10.1016/j.nmd.2007.04.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nmd.2007.04.006</ArticleId>
            <ArticleId IdType="pubmed">17560787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rubio J.C., Gomez-Gallego F., Santiago C., Garcia-Consuegra I., Perez M., Barriopedro M.I., Andreu A.L., Martin M.A., Arenas J., Lucia A. Genotype modulators of clinical severity in McArdle disease. Neurosci. Lett. 2007;422:217–222. doi: 10.1016/j.neulet.2007.06.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neulet.2007.06.025</ArticleId>
            <ArticleId IdType="pubmed">17630210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pizzamiglio C., Mahroo O.A., Khan K.N., Patasin M., Quinlivan R. Phenotype and genotype of 197 British patients with McArdle disease: An observational single-centre study. J. Inherit. Metab. Dis. 2021;44:1409–1418. doi: 10.1002/jimd.12438.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jimd.12438</ArticleId>
            <ArticleId IdType="pubmed">34534370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin M.A., Rubio J.C., Buchbinder J., Fernandez-Hojas R., del Hoyo P., Teijeira S., Gamez J., Navarro C., Fernandez J.M., Cabello A., et al.  Molecular heterogeneity of myophosphorylase deficiency (McArdle’s disease): A genotype-phenotype correlation study. Ann. Neurol. 2001;50:574–581. doi: 10.1002/ana.1225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.1225</ArticleId>
            <ArticleId IdType="pubmed">11706962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mate-Munoz J.L., Moran M., Perez M., Chamorro-Vina C., Gomez-Gallego F., Santiago C., Chicharro L., Foster C., Nogales-Gadea G., Rubio J.C., et al.  Favorable responses to acute and chronic exercise in McArdle patients. Clin. J. Sport Med. 2007;17:297–303. doi: 10.1097/JSM.0b013e3180f6168c.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/JSM.0b013e3180f6168c</ArticleId>
            <ArticleId IdType="pubmed">17620784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nogales-Gadea G., Consuegra-Garcia I., Rubio J.C., Arenas J., Cuadros M., Camara Y., Torres-Torronteras J., Fiuza-Luces C., Lucia A., Martin M.A., et al.  A transcriptomic approach to search for novel phenotypic regulators in McArdle disease. PLoS ONE. 2012;7:e31718.  doi: 10.1371/journal.pone.0031718.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0031718</ArticleId>
            <ArticleId IdType="pmc">PMC3276513</ArticleId>
            <ArticleId IdType="pubmed">22347505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nogales-Gadea G., Santalla A., Brull A., de Luna N., Lucia A., Pinos T. The pathogenomics of McArdle disease–genes, enzymes, models, and therapeutic implications. J. Inherit. Metab. Dis. 2015;38:221–230. doi: 10.1007/s10545-014-9743-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10545-014-9743-2</ArticleId>
            <ArticleId IdType="pubmed">25053163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez-Gomez I., Santalla A., Diez-Bermejo J., Munguia-Izquierdo D., Alegre L.M., Nogales-Gadea G., Arenas J., Martin M.A., Lucia A., Ara I. Sex Differences and the Influence of an Active Lifestyle on Adiposity in Patients with McArdle Disease. Int. J. Environ. Res. Public Health. 2020;17:4334.  doi: 10.3390/ijerph17124334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijerph17124334</ArticleId>
            <ArticleId IdType="pmc">PMC7344565</ArticleId>
            <ArticleId IdType="pubmed">32560448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nogales-Gadea G., Pinos T., Lucia A., Arenas J., Camara Y., Brull A., de Luna N., Martin M.A., Garcia-Arumi E., Marti R., et al.  Knock-in mice for the R50X mutation in the PYGM gene present with McArdle disease. Pt 7Brain. 2012;135:2048–2057. doi: 10.1093/brain/aws141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/aws141</ArticleId>
            <ArticleId IdType="pubmed">22730558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fiuza-Luces C., Nogales-Gadea G., Garcia-Consuegra I., Pareja-Galeano H., Rufian-Vazquez L., Perez L.M., Andreu A.L., Arenas J., Martin M.A., Pinos T., et al.  Muscle Signaling in Exercise Intolerance: Insights from the McArdle Mouse Model. Med. Sci. Sports Exerc. 2016;48:1448–1458. doi: 10.1249/MSS.0000000000000931.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1249/MSS.0000000000000931</ArticleId>
            <ArticleId IdType="pubmed">27031745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tarraso G., Real-Martinez A., Pares M., Romero-Cortadellas L., Puigros L., Moya L., de Luna N., Brull A., Martin M.A., Arenas J., et al.  Absence of p.R50X Pygm read-through in McArdle disease cellular models. Dis. Model. Mech. 2020;13:dmm043281. doi: 10.1242/dmm.043281.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/dmm.043281</ArticleId>
            <ArticleId IdType="pmc">PMC6994938</ArticleId>
            <ArticleId IdType="pubmed">31848135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McNamara E.L., Taylor R.L., Clayton J.S., Goullee H., Dilworth K.L., Pinos T., Brull A., Alexander I.E., Lisowski L., Ravenscroft G., et al.  Systemic AAV8-mediated delivery of a functional copy of muscle glycogen phosphorylase (Pygm) ameliorates disease in a murine model of McArdle disease. Hum. Mol. Genet. 2020;29:20–30. doi: 10.1093/hmg/ddz214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddz214</ArticleId>
            <ArticleId IdType="pubmed">31511858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krag T.O., Pinos T., Nielsen T.L., Brull A., Andreu A.L., Vissing J. Differential Muscle Involvement in Mice and Humans Affected by McArdle Disease. J. Neuropathol. Exp. Neurol. 2016;75:441–454. doi: 10.1093/jnen/nlw018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnen/nlw018</ArticleId>
            <ArticleId IdType="pubmed">27030740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Squire J. Special Issue: The Actin-Myosin Interaction in Muscle: Background and Overview. Int. J. Mol. Sci. 2019;20:5715.  doi: 10.3390/ijms20225715.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms20225715</ArticleId>
            <ArticleId IdType="pmc">PMC6887992</ArticleId>
            <ArticleId IdType="pubmed">31739584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu H., Van Remmen H. The SarcoEndoplasmic Reticulum Calcium ATPase (SERCA) pump: A potential target for intervention in aging and skeletal muscle pathologies. Skelet. Muscle. 2021;11:25. doi: 10.1186/s13395-021-00280-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13395-021-00280-7</ArticleId>
            <ArticleId IdType="pmc">PMC8588740</ArticleId>
            <ArticleId IdType="pubmed">34772465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Odermatt A., Taschner P.E., Khanna V.K., Busch H.F., Karpati G., Jablecki C.K., Breuning M.H., MacLennan D.H. Mutations in the gene-encoding SERCA1, the fast-twitch skeletal muscle sarcoplasmic reticulum Ca2+ ATPase, are associated with Brody disease. Nat. Genet. 1996;14:191–194. doi: 10.1038/ng1096-191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng1096-191</ArticleId>
            <ArticleId IdType="pubmed">8841193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voit A., Patel V., Pachon R., Shah V., Bakhutma M., Kohlbrenner E., McArdle J.J., Dell’Italia L.J., Mendell J.R., Xie L.H., et al.  Reducing sarcolipin expression mitigates Duchenne muscular dystrophy and associated cardiomyopathy in mice. Nat. Commun. 2017;8:1068. doi: 10.1038/s41467-017-01146-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-017-01146-7</ArticleId>
            <ArticleId IdType="pmc">PMC5648780</ArticleId>
            <ArticleId IdType="pubmed">29051551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghahramani Seno M.M., Trollet C., Athanasopoulos T., Graham I.R., Hu P., Dickson G. Transcriptomic analysis of dystrophin RNAi knockdown reveals a central role for dystrophin in muscle differentiation and contractile apparatus organization. BMC Genom. 2010;11:345.  doi: 10.1186/1471-2164-11-345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2164-11-345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prestori F., Moccia F., D’Angelo E. Disrupted Calcium Signaling in Animal Models of Human Spinocerebellar Ataxia (SCA) Int. J. Mol. Sci. 2019;21:216.  doi: 10.3390/ijms21010216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms21010216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meimaridou E., Lobos E., Hothersall J.S. Renal oxidative vulnerability due to changes in mitochondrial-glutathione and energy homeostasis in a rat model of calcium oxalate urolithiasis. Am. J. Physiol.-Renal Physiol. 2006;291:F731–F740. doi: 10.1152/ajprenal.00024.2006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajprenal.00024.2006</ArticleId>
            <ArticleId IdType="pubmed">16670437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murakami K., Yumoto F., Ohki S.Y., Yasunaga T., Tanokura M., Wakabayashi T. Structural basis for calcium-regulated relaxation of striated muscles at interaction sites of troponin with actin and tropomyosin. Adv. Exp. Med. Biol. 2007;592:71–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17278357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee F.X., Houweling P.J., North K.N., Quinlan K.G. How does alpha-actinin-3 deficiency alter muscle function? Mechanistic insights into ACTN3, the ‘gene for speed’. Biochim. Biophys. Acta. 2016;1863:686–693. doi: 10.1016/j.bbamcr.2016.01.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbamcr.2016.01.013</ArticleId>
            <ArticleId IdType="pubmed">26802899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Llavero F., Arrazola Sastre A., Luque Montoro M., Martin M.A., Arenas J., Lucia A., Zugaza J.L. Small GTPases of the Ras superfamily and glycogen phosphorylase regulation in T cells. Small GTPases. 2021;12:106–113. doi: 10.1080/21541248.2019.1665968.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/21541248.2019.1665968</ArticleId>
            <ArticleId IdType="pmc">PMC7849735</ArticleId>
            <ArticleId IdType="pubmed">31512989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lambert M., Bastide B., Cieniewski-Bernard C. Involvement of O-GlcNAcylation in the Skeletal Muscle Physiology and Physiopathology: Focus on Muscle Metabolism. Front. Endocrinol. 2018;9:578. doi: 10.3389/fendo.2018.00578.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fendo.2018.00578</ArticleId>
            <ArticleId IdType="pmc">PMC6232757</ArticleId>
            <ArticleId IdType="pubmed">30459708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lambert M., Claeyssen C., Bastide B., Cieniewski-Bernard C. O-GlcNAcylation as a regulator of the functional and structural properties of the sarcomere in skeletal muscle: An update review. Acta Physiol. 2020;228:e13301. doi: 10.1111/apha.13301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/apha.13301</ArticleId>
            <ArticleId IdType="pubmed">31108020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meyer J.G. Deep learning neural network tools for proteomics. Cell Rep. Methods. 2021;1:100003. doi: 10.1016/j.crmeth.2021.100003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.crmeth.2021.100003</ArticleId>
            <ArticleId IdType="pmc">PMC9017218</ArticleId>
            <ArticleId IdType="pubmed">35475237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Consuegra I., Blazquez A., Rubio J.C., Arenas J., Ballester-Lopez A., Gonzalez-Quintana A., Andreu A.L., Pinos T., Coll-Canti J., Lucia A., et al.  Taking advantage of an old concept, “illegitimate transcription”, for a proposed novel method of genetic diagnosis of McArdle disease. Genet. Med. 2016;18:1128–1135. doi: 10.1038/gim.2015.219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/gim.2015.219</ArticleId>
            <ArticleId IdType="pubmed">26913921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shevchenko A., Wilm M., Vorm O., Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 1996;68:850–858. doi: 10.1021/ac950914h.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/ac950914h</ArticleId>
            <ArticleId IdType="pubmed">8779443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kocher T., Pichler P., Schutzbier M., Stingl C., Kaul A., Teucher N., Hasenfuss G., Penninger J.M., Mechtler K. High precision quantitative proteomics using iTRAQ on an LTQ Orbitrap: A new mass spectrometric method combining the benefits of all. J. Proteome Res. 2009;8:4743–4752. doi: 10.1021/pr900451u.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/pr900451u</ArticleId>
            <ArticleId IdType="pubmed">19663507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alonso R., Pisa D., Marina A.I., Morato E., Rabano A., Rodal I., Carrasco L. Evidence for fungal infection in cerebrospinal fluid and brain tissue from patients with amyotrophic lateral sclerosis. Int. J. Biol. Sci. 2015;11:546–558. doi: 10.7150/ijbs.11084.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/ijbs.11084</ArticleId>
            <ArticleId IdType="pmc">PMC4400386</ArticleId>
            <ArticleId IdType="pubmed">25892962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benjamini Y., Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J. R. Stat. Soc. Ser. B (Methodol.) 1995;57:289–300. doi: 10.1111/j.2517-6161.1995.tb02031.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.2517-6161.1995.tb02031.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Segú-Vergés C., Coma M., Kessel C., Smeets S., Foell D., Aldea A. Application of systems biology-based in silico tools to optimize treatment strategy identification in Still’s disease. Arthritis Res. Ther. 2021;23:126. doi: 10.1186/s13075-021-02507-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13075-021-02507-w</ArticleId>
            <ArticleId IdType="pmc">PMC8063416</ArticleId>
            <ArticleId IdType="pubmed">33892792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanehisa M., Goto S., Kawashima S., Nakaya A. The KEGG databases at GenomeNet. Nucleic Acids Res. 2002;30:42–46. doi: 10.1093/nar/30.1.42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/30.1.42</ArticleId>
            <ArticleId IdType="pmc">PMC99091</ArticleId>
            <ArticleId IdType="pubmed">11752249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fabregat A., Jupe S., Matthews L., Sidiropoulos K., Gillespie M., Garapati P., Haw R., Jassal B., Korninger F., May B., et al.  The Reactome Pathway Knowledgebase. Nucleic Acids Res. 2018;46:D649–D655. doi: 10.1093/nar/gkx1132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkx1132</ArticleId>
            <ArticleId IdType="pmc">PMC5753187</ArticleId>
            <ArticleId IdType="pubmed">29145629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kerrien S., Aranda B., Breuza L., Bridge A., Broackes-Carter F., Chen C., Duesbury M., Dumousseau M., Feuermann M., Hinz U., et al.  The IntAct molecular interaction database in 2012. Nucleic Acids Res. 2012;40:D841–D846. doi: 10.1093/nar/gkr1088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkr1088</ArticleId>
            <ArticleId IdType="pmc">PMC3245075</ArticleId>
            <ArticleId IdType="pubmed">22121220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oughtred R., Stark C., Breitkreutz B.J., Rust J., Boucher L., Chang C., Kolas N., O’Donnell L., Leung G., McAdam R., et al.  The BioGRID interaction database: 2019 update. Nucleic Acids Res. 2019;47:D529–D541. doi: 10.1093/nar/gky1079.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gky1079</ArticleId>
            <ArticleId IdType="pmc">PMC6324058</ArticleId>
            <ArticleId IdType="pubmed">30476227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keshava Prasad T.S., Goel R., Kandasamy K., Keerthikumar S., Kumar S., Mathivanan S., Telikicherla D., Raju R., Shafreen B., Venugopal A., et al.  Human Protein Reference Database--2009 update. Nucleic Acids Res. 2009;37:D767–D772. doi: 10.1093/nar/gkn892.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkn892</ArticleId>
            <ArticleId IdType="pmc">PMC2686490</ArticleId>
            <ArticleId IdType="pubmed">18988627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Licata L., Briganti L., Peluso D., Perfetto L., Iannuccelli M., Galeota E., Sacco F., Palma A., Nardozza A.P., Santonico E., et al.  MINT, the molecular interaction database: 2012 update. Nucleic Acids Res. 2012;40:D857–D861. doi: 10.1093/nar/gkr930.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkr930</ArticleId>
            <ArticleId IdType="pmc">PMC3244991</ArticleId>
            <ArticleId IdType="pubmed">22096227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perez-Riverol Y., Bai J., Bandla C., Garcia-Seisdedos D., Hewapathirana S., Kamatchinathan S., Kundu D.J., Prakash A., Frericks-Zipper A., Eisenacher M., et al.  The PRIDE database resources in 2022: A hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 2022;50:D543–D552. doi: 10.1093/nar/gkab1038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkab1038</ArticleId>
            <ArticleId IdType="pmc">PMC8728295</ArticleId>
            <ArticleId IdType="pubmed">34723319</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
